News Seattle Genetics plans to file breast cancer drug tucatinib Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.
News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
